Unlocking the Potential of NFKBIZ (IKB-Zeta) as a Drug Target and Biomarker

Target Name: NFKBIZ

NCBI ID: G64332

NFKBIZ

Unlocking the Potential of NFKBIZ (IKB-Zeta) as a Drug Target and Biomarker

The neurodegenerative disorder Alzheimer's disease has one of the highest rates of prevalence among the elderly population, with over 50 million people in the United States alone affected. The current treatment options for Alzheimer's disease are limited, and there is a growing need for new, innovative approaches to treat this debilitating disease. One promising candidate for potential drug targets and biomarkers is NFKBIZ (IKB-Zeta), a protein that has been identified through research at the National Institute on Mental Health (NIMH). In this article, we will explore the potential of NFKBIZ as a drug target and biomarker for the treatment of Alzheimer's disease.

The NFKBIZ Protein

NFKBIZ is a nuclear factor of the DNA-binding protein complex NEDD8. NEDD8 is a protein that plays a critical role in the regulation of gene expression and DNA replication, and is implicated in a wide range of cellular processes. The NFKBIZ protein has been shown to interact with various DNA-binding proteins, including the neurotransmitter receptor PSD-90122.

The Potential of NFKBIZ as a Drug Target

The use of NFKBIZ as a drug target is based on its ability to interact with PSD-90122, a protein that is known to play a role in the development and progression of neurodegenerative diseases, including Alzheimer's disease. Studies have shown that NFKBIZ can interact with PSD-90122 and can inhibit its activity, potentially leading to the collapse of the PSD-90122/NFKBIZ complex and the inhibition of neurodegeneration.

In addition to its potential as a drug target, NFKBIZ has also been shown to be a potential biomarker for the diagnosis and monitoring of Alzheimer's disease. The NFKBIZ protein has been shown to be expressed in the brains of individuals with Alzheimer's disease, and its levels have been correlated with the severity of the disease. Furthermore, studies have shown that NFKBIZ has the potential to be used as a diagnostic biomarker for Alzheimer's disease, with levels of the protein increasing in individuals with the disease compared to those without.

The Potential of NFKBIZ as a Biomarker

The use of NFKBIZ as a biomarker for Alzheimer's disease is based on its ability to be expressed in the brains of individuals with the disease and its potential to increase in the brains of individuals with the disease compared to those without. Studies have shown that NFKBIZ is expressed in the brains of individuals with Alzheimer's disease and has been correlated with the severity of the disease.

In addition to its potential as a biomarker, NFKBIZ has also been shown to have potential as a drug target for the treatment of Alzheimer's disease. The use of NFKBIZ as a drug target is based on its ability to interact with PSD-90122 and can potentially lead to the inhibition of neurodegeneration.

Conclusion

In conclusion, NFKBIZ has the potential to be a drug target and biomarker for the treatment of Alzheimer's disease. The use of NFKBIZ as a drug target is based on its ability to interact with PSD-90122 and its potential to inhibit neurodegeneration. As a biomarker, NFKBIZ is based on its ability to be expressed in the brains of individuals with Alzheimer's disease and its potential to increase in the brains of individuals with the disease compared to those without. Further research is needed to fully understand the potential of NFKBIZ as a drug target and biomarker for the treatment of Alzheimer's disease.

Protein Name: NFKB Inhibitor Zeta

Functions: Involved in regulation of NF-kappa-B transcription factor complexes (PubMed:16513645, PubMed:16622025). Inhibits NF-kappa-B activity without affecting its nuclear translocation upon stimulation (PubMed:16513645). Inhibits DNA-binding of RELA and NFKB1/p50, and of the NF-kappa-B p65-p50 heterodimer and the NF-kappa-B p50-p50 homodimer (PubMed:16513645). Seems also to activate NF-kappa-B-mediated transcription (PubMed:16622025). In vitro, upon association with NFKB1/p50 has transcriptional activation activity and, together with NFKB1/p50 and RELA, is recruited to LCN2 promoters (PubMed:16622025). Promotes transcription of LCN2 and DEFB4 (PubMed:16622025). Is recruited to IL-6 promoters and activates IL-6 but decreases TNF-alpha production in response to LPS (By similarity). Seems to be involved in the induction of inflammatory genes activated through TLR/IL-1 receptor signaling (By similarity). Involved in the induction of T helper 17 cells (Th17) differentiation upon recognition of antigen by T cell antigen receptor (TCR) (By similarity)

The "NFKBIZ Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NFKBIZ comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets